Announcements and Circulars
- Global
-
2025-04-252024 Annual Report
-
2025-04-03Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2025
-
2025-03-27VOLUNTARY ANNOUNCEMENT MRG003 CLINICAL TRIAL RESULTS SELECTED AS LBA FOR ORAL PRESENTATION AT 2025 ASCO ANNUAL MEETING
-
2025-03-27ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024
-
2025-03-17NOTICE OF BOARD MEETING
-
2025-03-06Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2025
-
2025-03-04VOLUNTARY ANNOUNCEMENT UPDATE ON NEW DRUG APPLICATION OF MRG003
-
2025-02-06Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2025
-
2025-01-22INSIDE INFORMATION ANNOUNCEMENT EXCLUSIVE LICENSE AGREEMENT FOR NOVEL ADC MRG007
-
2025-01-07CHANGE OF ADDRESS OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG
-
2025-01-07POLL RESULTS OF THE 2025 FIRST EXTRAORDINARY GENERAL MEETING HELD ON JANUARY 7, 2025
-
2025-01-07Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2024
-
2024-12-17CONTINUING CONNECTED TRANSACTION
-
2024-12-17CONTINUING CONNECTED TRANSACTION
-
2024-12-17NOTICE OF 2025 FIRST EXTRAORDINARY GENERAL MEETING
-
2024-12-17PROXY FORM FOR USE AT THE 2025 FIRST EXTRAORDINARY GENERAL MEETING
-
2024-12-17(1) CONTINUING CONNECTED TRANSACTION IN RELATION TO CDMO SERVICES FRAMEWORK AGREEMENT (2) PROPOSED CHANGE OF THE AUDITOR AND (3) NOTICE OF THE 2025 FIRST EXTRAORDINARY GENERAL MEETING
-
2024-12-16CLOSURE OF REGISTER OF MEMBERS FOR THE 2025 FIRST EXTRAORDINARY GENERAL MEETINGS TO BE HELD ON JANUARY 7, 2025
-
2024-12-05Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2024
-
2024-11-26CONTINUING CONNECTED TRANSACTION CDMO SERVICES FRAMEWORK AGREEMENT
-
2024-11-26ANNOUNCEMENT OF PROPOSED CHANGE OF AUDITOR
-
2024-11-26CONTINUING CONNECTED TRANSACTION NEW PROCUREMENT FRAMEWORK AGREEMENT
-
2024-11-05Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024
-
2024-10-07Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024
-
2024-09-27VOLUNTARY ANNOUNCEMENT ACCEPTANCE OF THE NEW DRUG APPLICATION AND PRIORITY REVIEW GRANTED BY NMPA TO MRG003 FOR THE TREATMENT OF R/M NPC
-
2024-09-242024 Interim Report
-
2024-09-04Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024
-
2024-09-02ARTICLES OF ASSOCIATION
-
2024-09-02AMENDMENTS TO THE ARTICLES OF ASSOCIATION
-
2024-08-21INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024
-
2024-08-09NOTICE OF BOARD MEETING
-
2024-08-06Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024
-
2024-08-05VOLUNTARY ANNOUNCEMENT BREAKTHROUGH THERAPY DESIGNATION GRANTED BY THE FDA TO MRG003 FOR THE TREATMENT OF R/M NPC
-
2024-07-05Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
-
2024-06-19POLL RESULTS OF THE 2023 ANNUAL GENERAL MEETING HELD ON JUNE 19, 2024
-
2024-06-06Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024
-
2024-05-28Proxy Form for the Annual General Meeting to be held on June 19 2024
-
2024-05-28(1) 2023 REPORT OF THE BOARD OF DIRECTORS (2) 2023 REPORT OF THE BOARD OF SUPERVISORS (3) 2023 ANNUAL REPORT (4) 2023 FINANCIAL ACCOUNTS REPORT (5) 2024 FINANCIAL BUDGET (6) 2023 ANNUAL PROFIT DISTRIBUTION PLAN (7) RE-APPOINTMENT OF AUDITOR (8) GENERAL MANDATE TO ISSUE ADDITIONAL SHARES AND NOTICE OF THE 2023 ANNUAL GENERAL MEETING
-
2024-05-28NOTICE OF THE 2023 ANNUAL GENERAL MEETING
-
2024-05-24Next Day Disclosure Return
-
2024-05-24COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE
-
2024-05-24VOLUNTARY ANNOUNCEMENT THREE CLINICAL TRIAL RESULTS PRESENTED AT 2024 ASCO ANNUAL MEETING
-
2024-05-17Placing of New H Shares under General Mandate
-
2024-05-06Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024
-
2024-04-252023 Annual Report
-
2024-04-15VOLUNTARY ANNOUNCEMENT UPDATE ON THE LICENSE AGREEMENT WITH ASTRAZENECA FOR CMG901
-
2024-04-03Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
-
2024-03-27ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
-
2024-03-15NOTICE OF BOARD MEETING
-
2024-03-11VOLUNTARY ANNOUNCEMENT FAST TRACK DESIGNATION GRANTED BY THE FDA TO MRG004A FOR THE TREATMENT OF PANCREATIC CANCER
-
2024-03-05Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
-
2024-02-05Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
-
2024-01-31ARTICLES OF ASSOCIATION
-
2024-01-31List of Directors and their Roles and Functions
-
2024-01-31(1) POLL RESULTS OF THE 2024 SECOND EXTRAORDINARY GENERAL MEETING HELD ON JANUARY 31, 2024; (2) RE-ELECTION OF DIRECTORS AND SUPERVISORS; (3) CHANGE OF EMPLOYEE REPRESENTATIVE SUPERVISOR; AND (4) AMENDMENTS TO THE ARTICLES OF ASSOCIATION
-
2024-01-31(1) POLL RESULTS OF THE 2024 SECOND EXTRAORDINARY GENERAL MEETING HELD ON JANUARY 31, 2024; (2) RE-ELECTION OF DIRECTORS AND SUPERVISORS; (3) CHANGE OF EMPLOYEE REPRESENTATIVE SUPERVISOR; AND (4) AMENDMENTS TO THE ARTICLES OF ASSOCIATION
-
2024-01-31POLL RESULTS OF THE 2024 FIRST EXTRAORDINARY GENERAL MEETING HELD ON JANUARY 31, 2024
-
2024-01-16NOTICE OF THE 2024 SECOND EXTRAORDINARY GENERAL MEETING
-
2024-01-16PROXY FORM FOR USE AT THE 2024 SECOND EXTRAORDINARY GENERAL MEETING
-
2024-01-16(1) RESOLUTIONS RELATING TO THE PROPOSED RE-ELECTION OF THE BOARD OF DIRECTORS; (2) PROPOSED RE-ELECTION OF SUPERVISORS; (3) PROPOSED AMENDMENTS OF THE ARTICLES OF ASSOCIATION; AND (4) NOTICE OF THE 2024 SECOND EXTRAORDINARY GENERAL MEETING
-
2024-01-16(1) RESOLUTIONS RELATING TO THE PROPOSED RE-ELECTION OF THE BOARD OF DIRECTORS; (2) PROPOSED RE-ELECTION OF SUPERVISORS; (3) PROPOSED AMENDMENTS OF THE ARTICLES OF ASSOCIATION; AND (4) NOTICE OF THE 2024 SECOND EXTRAORDINARY GENERAL MEETING
-
2024-01-16(1) PROPOSED RE-ELECTION OF THE BOARD OF DIRECTORS; (2) RETIREMENT OF CO-CHIEF EXECUTIVE OFFICER AND DIRECTORS; (3) PROPOSED RE-ELECTION OF SUPERVISORS; AND (4) PROPOSED AMENDMENTS OF THE ARTICLES OF ASSOCIATION
-
2024-01-16(1) PROPOSED RE-ELECTION OF THE BOARD OF DIRECTORS; (2) RETIREMENT OF CO-CHIEF EXECUTIVE OFFICER AND DIRECTORS; (3) PROPOSED RE-ELECTION OF SUPERVISORS; AND (4) PROPOSED AMENDMENTS OF THE ARTICLES OF ASSOCIATION
-
2024-01-16CONTINUING CONNECTED TRANSACTION
-
2024-01-16NOTICE OF THE 2024 FIRST EXTRAORDINARY GENERAL MEETING
-
2024-01-16PROXY FORM FOR USE AT THE 2024 FIRST EXTRAORDINARY GENERAL MEETING
-
2024-01-16(1) CONTINUING CONNECTED TRANSACTION IN RELATION TO CDMO SERVICES FRAMEWORK AGREEMENT AND THE SUPPLEMENTAL CDMO SERVICES FRAMEWORK AGREEMENT AND (2) NOTICE OF THE 2024 FIRST EXTRAORDINARY GENERAL MEETING
-
2024-01-16Notification Letter with Request Form to Non-Registered Shareholders
-
2024-01-16Notification Letter with Request Form to Registered Shareholders
-
2024-01-11CLOSURE OF REGISTER OF MEMBERS FOR THE 2024 FIRST AND SECOND EXTRAORDINARY GENERAL MEETINGS TO BE HELD ON JANUARY 31, 2024
-
2024-01-04Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
-
2023-12-29VOLUNTARY ANNOUNCEMENT COMPLETION OF PATIENT ENROLLMENT OF PIVOTAL PHASE IIb CLINICAL TRIAL FOR MRG003 FOR THE TREATMENT OF R/M NPC
-
2023-12-29VOLUNTARY ANNOUNCEMENT COMPLETION OF PATIENT ENROLLMENT OF PIVOTAL PHASE IIb CLINICAL TRIAL FOR MRG003 FOR THE TREATMENT OF R/M NPC
-
2023-12-22ANNOUNCEMENT IN RELATION TO THE CONTINUING CONNECTED TRANSACTION THE SUPPLEMENTAL CDMO SERVICES FRAMEWORK AGREEMENT AND THE PROPOSED REVISED CAP
-
2023-12-22CONTINUING CONNECTED TRANSACTION NEW PROCUREMENT FRAMEWORK AGREEMENT
-
2023-12-14VOLUNTARY ANNOUNCEMENT ORPHAN-DRUG DESIGNATION GRANTED BY THE FDA TO MRG004A FOR THE TREATMENT OF PANCREATIC CANCER
-
2023-12-08ANNOUNCEMENT DELAY IN DESPATCH OF CIRCULAR AND CANCELLATION OF BOOK CLOSURE PERIOD
-
2023-12-04CLOSURE OF REGISTER OF MEMBERS FOR THE 2023 SECOND EXTRAORDINARY GENERAL MEETING TO BE HELD ON DECEMBER 22, 2023
-
2023-12-04Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
-
2023-12-04VOLUNTARY ANNOUNCEMENT FAST TRACK DESIGNATION GRANTED BY THE FDA TO MRG003 FOR THE TREATMENT OF R/M NPC
-
2023-12-04VOLUNTARY ANNOUNCEMENT FAST TRACK DESIGNATION GRANTED BY THE FDA TO MRG003 FOR THE TREATMENT OF R/M NPC
-
2023-11-17ANNOUNCEMENT POSTPONEMENT OF EXTRAORDINARY GENERAL MEETING AND CANCELLATION OF BOOK CLOSURE PERIOD
-
2023-11-14NOTICE OF THE 2023 SECOND EXTRAORDINARY GENERAL MEETING
-
2023-11-14PROXY FORM FOR USE AT THE 2023 SECOND EXTRAORDINARY GENERAL MEETING
-
2023-11-14RESOLUTIONS RELATING TO THE PROPOSED ADDITIONAL METHOD FOR THE PUBLIC TRADING ON THE PRC DOMESTIC CAPITAL MARKET AND PROPOSED AMENDMENTS TO THE ARTICLES ANCILLARY TO THE PROPOSED QUOTATION
-
2023-11-14(1) RESOLUTIONS RELATING TO THE PROPOSED ADDITIONAL METHOD FOR THE PUBLIC TRADING ON THE PRC DOMESTIC CAPITAL MARKET; (2) PROPOSED AMENDMENTS TO THE ARTICLES ANCILLARY TO THE PROPOSED QUOTATION; AND (3) NOTICE OF THE 2023 SECOND EXTRAORDINARY GENERAL MEETING
-
2023-11-14(1) RESOLUTIONS RELATING TO THE PROPOSED ADDITIONAL METHOD FOR THE PUBLIC TRADING ON THE PRC DOMESTIC CAPITAL MARKET; (2) PROPOSED AMENDMENTS TO THE ARTICLES ANCILLARY TO THE PROPOSED QUOTATION; AND (3) NOTICE OF THE 2023 SECOND EXTRAORDINARY GENERAL MEETING
-
2023-11-13CONTINUING CONNECTED TRANSACTION CDMO SERVICES FRAMEWORK AGREEMENT
-
2023-11-09CLOSURE OF REGISTER OF MEMBERS FOR THE 2023 SECOND EXTRAORDINARY GENERAL MEETING TO BE HELD ON NOVEMBER 29, 2023
-
2023-11-03Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023
-
2023-10-03Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2023
-
2023-09-29DISCLOSEABLE TRANSACTION DISPOSAL OF 15% EQUITY INTEREST IN AN ASSOCIATE
-
2023-09-222023 Interim Report
-
2023-09-05Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2023
-
2023-08-25POLL RESULTS OF THE 2023 FIRST EXTRAORDINARY GENERAL MEETING HELD ON AUGUST 25, 2023
-
2023-08-25INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2023
-
2023-08-15NOTICE OF BOARD MEETING
-
2023-08-09PROXY FORM FOR USE AT THE 2023 FIRST EXTRAORDINARY GENERAL MEETING
-
2023-08-09NOTICE OF THE 2023 FIRST EXTRAORDINARY GENERAL MEETING
-
2023-08-09PROPOSED EXTENSION OF THE VALIDITY PERIOD OF THE RESOLUTIONS CONCERNING THE PROPOSED ISSUE OF A SHARES AND LISTING ON THE SCI-TECH BOARD, PROPOSED EXTENSION OF THE VALIDITY PERIOD OF THE RESOLUTION AUTHORIZING THE BOARD OF DIRECTORS AND PERSONS AUTHORIZED BY IT TO FULLY HANDLE THE RELEVANT MATTERS IN CONNECTION WITH THE ISSUE OF A SHARES AND LISTING ON THE SCI-TECH BOARD AND NOTICE OF EGM
-
2023-08-04Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2023
-
2023-08-01ARTICLES OF ASSOCIATION
-
2023-08-01VOLUNTARY ANNOUNCEMENT IN RELATION TO THE PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
-
2023-07-11PROPOSED EXTENSION OF THE VALIDITY PERIOD OF THE RESOLUTIONS CONCERNING THE ISSUE OF A SHARES AND LISTING ON THE SCI-TECH BOARD AND OTHER ANCILLARY RESOLUTIONS AND CLOSURE OF REGISTER OF MEMBERS
-
2023-07-03Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2023
-
2023-06-15POLL RESULTS OF THE 2022 ANNUAL GENERAL MEETING AND CLASS MEETINGS HELD ON JUNE 15, 2023
-
2023-06-06Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2023
-
2023-05-24Proxy Form for the 2023 First Class Meeting of Domestic Shareholders
-
2023-05-24Proxy Form for the 2023 First Class Meeting of H Shareholders
-
2023-05-24Proxy Form for the Annual General Meeting to be held on June 15 2023
-
2023-05-24(1) 2022 REPORT OF THE BOARD OF DIRECTORS (2) 2022 REPORT OF THE BOARD OF SUPERVISORS (3) 2022 ANNUAL REPORT (4) 2022 FINANCIAL ACCOUNTS REPORT (5) 2023 FINANCIAL BUDGET (6) 2022 ANNUAL PROFIT DISTRIBUTION PLAN (7) RE-APPOINTMENT OF AUDITOR (8) PROPOSED AMENDMENTS TO ARTICLES IN RESPECT OF TRIAL MEASURES (9) PROPOSED AMENDMENTS TO ARTICLES IN RESPECT OF PROPOSED ISSUE OF A SHARES (10) GENERAL MANDATE TO ISSUE ADDITIONAL SHARES AND NOTICES OF THE 2022 ANNUAL GENERAL MEETING AND THE CLASS MEETINGS
-
2023-05-24NOTICE OF THE 2023 FIRST CLASS MEETING OF DOMESTIC SHAREHOLDERS
-
2023-05-24NOTICE OF THE 2023 FIRST CLASS MEETING OF H SHAREHOLDERS
-
2023-05-24NOTICE OF THE 2022 ANNUAL GENERAL MEETING
-
2023-05-03Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2023
-
2023-04-26CLOSURE OF REGISTER OF MEMBERS FOR ANNUAL GENERAL MEETING TO BE HELD ON JUNE 15, 2023
-
2023-04-26Terms of Reference for Remuneration and Appraisal Committee
-
2023-04-262022 Annual Report
-
2023-04-04Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2023
-
2023-03-17ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2022
-
2023-03-06NOTICE OF BOARD MEETING
-
2023-03-02Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2023
-
2023-02-23INSIDE INFORMATION ANNOUNCEMENT EXCLUSIVE LICENSE AGREEMENT WITH ASTRAZENECA FOR CMG901
-
2023-02-05VOLUNTARY ANNOUNCEMENT UPDATE ON THE DATA FROM PHASE Ia CLINICAL STUDY OF CMG901 PRESENTED AT THE 2023 ASCO GI CANCERS SYMPOSIUM
-
2023-02-02Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2023
-
2023-01-05Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2022
-
2022-12-02Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2022
-
2022-11-01Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2022
-
2022-10-03Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2022
-
2022-09-29VOLUNTARY ANNOUNCEMENT CONDITIONAL MARKETING APPROVAL OBTAINED IN CHINA FOR PUYOUHENG (PUCOTENLIMAB INJECTION) FOR THE TREATMENT OF INOPERABLE OR METASTATIC MELANOMA
-
2022-09-29VOLUNTARY ANNOUNCEMENT BREAKTHROUGH THERAPY DESIGNATION GRANTED BY THE CDE TO MRG003 FOR THE TREATMENT OF R/M NPC
-
2022-09-29VOLUNTARY ANNOUNCEMENT BREAKTHROUGH THERAPY DESIGNATION GRANTED BY THE CDE TO MRG003 FOR THE TREATMENT OF R/M NPC
-
2022-09-272022 Interim Report
-
2022-09-23(1) POLL RESULTS OF THE POSTPONED EGM AND POSTPONED CLASS MEETINGS HELD ON SEPTEMBER 23, 2022 AND (2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION, THE RULES OF PROCEDURES FOR THE MEETING OF SHAREHOLDERS, THE RULES OF PROCEDURES FOR THE MEETING OF BOARD OF DIRECTORS AND THE RULES OF PROCEDURES FOR THE MEETING OF SUPERVISORY COMMITTEE
-
2022-09-08REVISED PROXY FORM FOR USE AT THE POSTPONED 2022 FIRST CLASS MEETING OF DOMESTIC SHAREHOLDERS
-
2022-09-08REVISED PROXY FORM FOR USE AT THE POSTPONED 2022 FIRST CLASS MEETING OF H SHAREHOLDERS
-
2022-09-08REVISED PROXY FORM FOR USE AT THE POSTPONED 2022 FIRST EXTRAORDINARY GENERAL MEETING
-
2022-09-08SUPPLEMENTAL CIRCULAR IN RELATION TO PROPOSED ISSUE OF A SHARES AND LISTING ON THE SCI-TECH BOARD AND OTHER ANCILLARY RESOLUTIONS, POSTPONEMENT OF THE EGM AND CLASS MEETINGS AND NOTICES OF POSTPONED EGM AND POSTPONED CLASS MEETINGS
-
2022-09-08SUPPLEMENTAL NOTICE OF THE POSTPONED 2022 FIRST CLASS MEETING OF DOMESTIC SHAREHOLDERS
-
2022-09-08SUPPLEMENTAL NOTICE OF THE POSTPONED 2022 FIRST CLASS MEETING OF H SHAREHOLDERS
-
2022-09-08SUPPLEMENTAL NOTICE OF THE POSTPONED 2022 FIRST EXTRAORDINARY GENERAL MEETING
-
2022-09-08(1) REVISED INFORMATION IN RESPECT OF THE ISSUE OF A SHARES, (2) POSTPONEMENT OF EGM AND CLASS MEETINGS AND (3) EXTENSION OF CLOSURE OF REGISTER OF MEMBERS FOR THE POSTPONED EGM AND THE POSTPONED CLASS MEETING OF H SHAREHOLDERS
-
2022-09-05VOLUNTARY ANNOUNCEMENT INCLUSION OF THE COMPANY AS AN ELIGIBLE STOCK OF THE SHENZHEN-HONG KONG STOCK CONNECT
-
2022-09-05Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2022
-
2022-09-01PROXY FORM FOR USE AT THE 2022 FIRST CLASS MEETING OF DOMESTIC SHAREHOLDERS
-
2022-09-01PROXY FORM FOR USE AT THE 2022 FIRST CLASS MEETING OF H SHAREHOLDERS
-
2022-09-01PROXY FORM FOR USE AT THE 2022 FIRST EXTRAORDINARY GENERAL MEETING
-
2022-09-01(1) PROPOSED ISSUE OF A SHARES AND LISTING ON THE SCI-TECH BOARD AND OTHER ANCILLARY RESOLUTIONS; (2) PROPOSED AMENDMENTS TO THE ARTICLES ANCILLARY TO THE PROPOSED ISSUE OF A SHARES; (3) UNCOVERED DEFICIT OF THE COMPANY AMOUNTING TO MORE THAN ONE-THIRD OF THE TOTAL SHARE CAPITAL OF THE COMPANY; AND (4) NOTICES OF EGM AND CLASS MEETINGS
-
2022-09-01NOTICE OF THE 2022 FIRST CLASS MEETING OF DOMESTIC SHAREHOLDERS
-
2022-09-01NOTICE OF THE 2022 FIRST CLASS MEETING OF H SHAREHOLDERS
-
2022-09-01NOTICE OF THE 2022 FIRST EXTRAORDINARY GENERAL MEETING
-
2022-09-01PROPOSED ISSUE OF A SHARES AND LISTING ON THE SCI-TECH BOARD AND OTHER ANCILLARY RESOLUTIONS AND PROPOSED AMENDMENTS TO THE ARTICLES ANCILLARY TO THE PROPOSED ISSUE OF A SHARES AND UNCOVERED DEFICIT OF THE COMPANY AMOUNTING TO MORE THAN ONE-THIRD OF THE TOTAL SHARE CAPITAL OF THE COMPANY
-
2022-08-25INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2022
-
2022-08-21VOLUNTARY ANNOUNCEMENT INCLUSION OF THE COMPANY AS A CONSTITUENT STOCK OF HANG SENG INDEX
-
2022-08-15CHANGE OF ADDRESS OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG
-
2022-08-15NOTICE OF BOARD MEETING
-
2022-08-02Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2022
-
2022-08-01CLOSURE OF REGISTER OF MEMBERS FOR THE 2022 FIRST EXTRAORDINARY GENERAL MEETING TO BE HELD ON SEPTEMBER 16, 2022
-
2022-07-22INSIDE INFORMATION ANNOUNCEMENT CONDITIONAL MARKETING APPROVAL OBTAINED IN CHINA FOR PUYOUHENG (PUCOTENLIMAB INJECTION) FOR THE TREATMENT IN HIGH LEVELS OF MICROSATELLITE INSTABILITY/DEFICIENT MISMATCH REPAIR (MSI-H/DMMR)
-
2022-07-04Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2022
-
2022-06-21POLL RESULTS OF THE 2021 ANNUAL GENERAL MEETING HELD ON JUNE 21, 2022
-
2022-06-01Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2022
-
2022-05-27Proxy Form for the Annual General Meeting to be held on 21 June 2022
-
2022-05-27(1) 2021 REPORT OF THE BOARD OF DIRECTORS (2) 2021 REPORT OF THE BOARD OF SUPERVISORS (3) 2021 ANNUAL REPORT (4) 2021 FINANCIAL ACCOUNTS REPORT (5) 2022 FINANCIAL BUDGET (6) 2021 ANNUAL PROFIT DISTRIBUTION PLAN (7) RE-APPOINTMENT OF AUDITOR (8) GENERAL MANDATE TO ISSUE ADDITIONAL SHARES AND NOTICE OF 2021 ANNUAL GENERAL MEETING
-
2022-05-27NOTICE OF 2021 ANNUAL GENERAL MEETING
-
2022-05-27ARTICLES OF ASSOCIATION
-
2022-05-27AMENDMENTS TO THE ARTICLES OF ASSOCIATION
-
2022-05-03Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2022
-
2022-04-25CLOSURE OF REGISTER OF MEMBERS FOR ANNUAL GENERAL MEETING TO BE HELD ON JUNE 21, 2022
-
2022-04-252021 Annual Report
-
2022-04-01Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2022
-
2022-03-29ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2021
-
2022-03-22Next Day Disclosure Return
-
2022-03-17PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION, STABILIZING ACTIONS AND END OF STABILIZATION PERIOD
-
2022-03-17NOTICE OF BOARD MEETING
-
2022-03-03Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2022
-
2022-02-22Procedures for Shareholders to Nominate a Person as a Director
-
2022-02-22Board Diversity Policy
-
2022-02-22Shareholders Communication Policy
-
2022-02-22List of Directors and their Roles and Functions
-
2022-02-22Terms of Reference for Remuneration and Appraisal Committee
-
2022-02-22Terms of Reference for Nomination Committee
-
2022-02-22Terms of Reference for Audit Committee
-
2022-02-22Articles of Association
-
2022-02-22ANNOUNCEMENT OF OFFER PRICE AND ALLOTMENT RESULTS
-
2022-02-10GREEN APPLICATION FORM
-
2022-02-10GLOBAL OFFERING
-
2022-02-10GLOBAL OFFERING
-
2022-02-03PHIP (1st submission)
-
2022-02-03PHIP (1st submission)
-
2021-10-29Application Proof (1st submission)
-
2021-10-29Application Proof (1st submission)
